Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CCR2 | P41597 | 9/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125771 | 0.89 | CYP2C9 (0.49) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL127008 | 0.81 | CCR2 (0.61) | CYP3A4CCR2CYP2C9TSHR | |
| SCHEMBL125394 | 0.80 | CYP2C9 (0.59) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL130229 | 0.75 | CCR2 (0.53) | CYP3A4CCR2ALDH1A1TSHR | |
| SCHEMBL13623790 | 0.74 | CCR2 (0.39) | CYP3A4CCR2CYP2C9KMT2AALDH1A1 | |
| SCHEMBL21999085 | 0.73 | CYP2C9 (0.54) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL130335 | 0.73 | CYP2C9 (0.54) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL306117 | 0.73 | CYP2C9 (0.54) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL125770 | 0.72 | CYP2C9 (0.49) | CYP3A4CCR2CYP2C9 | |
| SCHEMBL13317637 | 0.71 | CYP2C9 (0.54) | CYP3A4CCR2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093247-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | CYP3A4 1214/4885CCR2 1/4885CYP2C9 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.